Klarin, Derek http://orcid.org/0000-0002-4636-5780
,
Lynch, Julie http://orcid.org/0000-0003-0108-2127
Aragam, Krishna
Chaffin, Mark http://orcid.org/0000-0002-1234-5562
Assimes, Themistocles L. http://orcid.org/0000-0003-2349-0009
Huang, Jie
Lee, Kyung Min http://orcid.org/0000-0001-8995-0448
Shao, Qing
Huffman, Jennifer E.
Natarajan, Pradeep
Arya, Shipra
Small, Aeron
Sun, Yan V.
Vujkovic, Marijana http://orcid.org/0000-0003-4924-5714
Freiberg, Matthew S.
Wang, Lu
Chen, Jinbo
Saleheen, Danish http://orcid.org/0000-0001-6193-020X
Lee, Jennifer S.
Miller, Donald R.
Reaven, Peter
Alba, Patrick R.
Patterson, Olga V. http://orcid.org/0000-0002-8717-5975
DuVall, Scott L. http://orcid.org/0000-0002-4898-3865
Boden, William E.
Beckman, Joshua A.
Gaziano, J. Michael
Concato, John
Rader, Daniel J.
Cho, Kelly
Chang, Kyong-Mi
Wilson, Peter W. F.
O’Donnell, Christopher J.
Kathiresan, Sekar
Tsao, Philip S.
Damrauer, Scott M. http://orcid.org/0000-0001-8009-1632
Article History
Received: 26 September 2018
Accepted: 17 May 2019
First Online: 8 July 2019
Competing interests
: J.A.B. reports consulting with AstraZeneca, Bristol Myers Squibb, Amgen, Merck, Sanofi, Antidote Pharmaceutical and Boehringer Ingelheim. He serves on the DSMC for Bayer and Novartis. S.L.D. has received research grant support from the following for-profit companies through the University of Utah or the Western Institute for Biomedical Research (VA Salt Lake City’s affiliated non-profit): AbbVie Inc., Anolinx LLC, Astellas Pharma Inc., AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim International GmbH, Celgene Corporation, Eli Lilly and Company, Genentech Inc., Genomic Health, Inc., Gilead Sciences Inc., GlaxoSmithKline PLC, Innocrin Pharmaceuticals Inc., Janssen Pharmaceuticals, Inc., Kantar Health, Myriad Genetic Laboratories, Inc., Novartis International AG and PAREXEL International Corporation. S.M.D. receives research support to his institution from CytoVAS and RenalytixAI. S.K. is a founder of Maze Therapeutics, Verve Therapeutics and San Therapeutics. He holds equity in Catabasis and San Therapeutics. He is a member of the scientific advisory boards for Regeneron Genetics Center and Corvidia Therapeutics; served as a consultant for Acceleron, Eli Lilly, Novartis, Merck, NovoNordisk, Novo Ventures, Ionis, Alnylam, Aegerion, Huag Partners, Noble Insights, Leerink Partners, Bayer Healthcare, Illumina, Color Genomics, MedGenome, Quest and Medscape; and reports patents related to a method of identifying and treating a person having a predisposition to or afflicted with cardiometabolic disease (20180010185) and a genetics risk predictor (20190017119). O.V.P. has received research grants from the following for-profit organizations through the University of Utah or Western Institute for Biomedical Research: Anolinx LLC, AstraZeneca Pharmaceuticals LP, Genentech Inc., Genomic Health, Inc., Gilead Sciences Inc., Janssen Pharmaceuticals, Inc., Novartis International AG and PAREXEL International Corporation.